Trials / Terminated
TerminatedNCT01804530
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent in Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Plexxikon · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.
Detailed description
Part 1. Open-label, sequential PLX7486 TsOH single-agent dose escalation in approximately 60 patients with solid tumors.
Conditions
- Solid Tumor
- Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations
- Tenosynovial Giant Cell Tumor
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PLX7486 TsOH | PLX7486 TsOH capsules, 50mg |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2018-01-24
- Completion
- 2018-01-24
- First posted
- 2013-03-05
- Last updated
- 2018-08-02
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01804530. Inclusion in this directory is not an endorsement.